Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 9/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116415 | 1.00 | BCHE (0.41) | BCHEMAOBLMNAMAPK1RAB9A | |
| SCHEMBL16115610 | 0.92 | BCHE (0.38) | BCHEMAOBLMNAMAPK1RAB9A | |
| SCHEMBL23120741 | 0.83 | CYP2D6 (0.41) | BCHEMAPK1 | |
| SCHEMBL5553304 | 0.81 | MAOB (0.40) | BCHEMAOBLMNAMAPK1RAB9A | |
| SCHEMBL299361 | 0.81 | PIK3CD (0.52) | BCHE | |
| SCHEMBL17093557 | 0.79 | ALDH1A1 (0.37) | HSD11B1 | |
| SCHEMBL21855165 | 0.78 | HSD17B10 (0.52) | BCHEMAOBMAOA | |
| SCHEMBL28005050 | 0.78 | ALDH1A1 (0.36) | LMNAMAPK1RAB9A | |
| SCHEMBL15870032 | 0.78 | LMNA (0.40) | BCHEMAOBLMNAMAOA | |
| SCHEMBL24247404 | 0.78 | LMNA (0.40) | BCHEMAOBLMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5559227-A | IMMUNOSUPPRESSANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2023156863-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-10662161-B2 | Pyrimidines and uses thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180215720-A1 | PYRIMIDINES AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-08-02 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| EP-3016948-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | Università Degli Studi Di Milano - Bicocca (IT) | 2016-05-11 | — | — | EP | disclosed |
| US-20060234927-A1 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-10-19 | — | — | US | disclosed |
| CN-1784232-A | Therapeutic agents comprising a combination of an anti-angiogenic agent and a Src inhibitor and therapeutic uses thereof | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| CN-1735617-A | Quinazoline derivatives as SRC tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-02-15 | — | — | CN | disclosed |
| US-5559227-A | IMMUNOSUPPRESSANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-5550133-A | TREATING RHEUMATOID ARTHRITIS IN MAMMAL | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-08-27 | — | — | US | disclosed |
| US-5504204-A | IMMUNOSUPPRESSIVE, ANTIINFLAMMATORY, ANTIFUNGAL, ANTIPROLIFERATIVE AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-02 | — | — | US | disclosed |
| US-5486522-A | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-23 | — | — | US | disclosed |
| US-5486524-A | RESTENOSIS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-23 | — | — | US | disclosed |
| US-5486523-A | ANTIINFLAMMATORY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-23 | — | — | US | disclosed |
| US-5480988-A | USEFUL AS AN IMMUNOSUPPRESSANT, ANTIINFLAMMATORY AGENT, FUNGICIDE, ANTIGROWTH AGENT OR ANTITUMOR AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | BCHE 1089/4885MAOB 1094/4885LMNA 2916/4885 |
| US-20060234927-A1 | Neuroprotective iron chelators and pharmaceutical compositions comprising them | FECH, HMOX1, FTH1 | BCHE 2020/4885MAOB 1223/4885LMNA 824/4885 |
| US-10662161-B2 | Pyrimidines and uses thereof | TYMS, DPYD, TYMP | BCHE 3403/4885MAOB 973/4885LMNA 4634/4885 |
| US-20180215720-A1 | PYRIMIDINES AND USES THEREOF | TYMS, DPYD, TYMP | BCHE 3403/4885MAOB 973/4885LMNA 4634/4885 |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | ALK, ERBB2, ABL1 | BCHE 4688/4885MAOB 2162/4885LMNA 2708/4885 |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, AXL, MET | BCHE 4532/4885MAOB 2895/4885LMNA 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.